Hosted on MSN10mon
FDA approves Phase III trial of GenFleet’s KRAS G12C inhibitorThe US Food and Drug Administration (FDA) has granted approval for GenFleet Therapeutics’ Phase III clinical trial of GFH925, a KRAS G12C inhibitor, for the treatment of patients with refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback